Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Dunad Therapeutics, a UK-based developer of protein degradation technology, launched yesterday with £5m ($7m) in funding from venture firm Epidarex Capital. Dunad advances research by co-founder, acting chief executive and chief scientific officer Prof Patrick Gunning, a researcher in University of Toronto Mississauga’s Department of Chemical and Physical Sciences.
Inotec AMD, a UK-based wound healing technology spinout of University of Cambridge, has pocketed £3.4m ($4.7m) in series C funding from Wealth Club. The spinout previously secured $9.1m in…